By Fineline Cube 
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in China. Approved in April 2024, the drug is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer with PIK3CA/AKT1/PTEN alterations. It is designed for patients who have experienced disease progression following at least one line of endocrine therapy in the metastatic setting or recurrence within 12 months of completing adjuvant therapy.
Market First
Capivasertib is the first and only AKT inhibitor approved in China for breast cancer patients with PIK3CA, AKT1, or PTEN alterations.
Clinical Results
Clinical data demonstrate that the capivasertib/fulvestrant combination reduces the risk of disease progression or death by 59% compared to fulvestrant alone. In Chinese patients with PIK3CA/AKT1/PTEN alterations, the median progression-free survival (PFS) was 5.7 months versus 1.9 months for fulvestrant alone.-Fineline Info & Tech